CDEK
← All drugs Report issue

vatiquinone

Small moleculeexperimental

Clinical trial activity

20 trials · 14 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
15
Phase 3
4
Phase 4
0

Earliest trial started Feb 1, 2010 (NCT01370447)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)=CCC/C(C)=C/CC/C(C)=C/CC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O
Mol. weight
440.67 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • alpha-tocotrienol quinone
  • epi-743
  • epi-743
  • epi-743
  • epi-743
  • (r)-alpha-tocotrienol quinone
  • (r)-alpha-tocotrienol quinone
  • vatiquinone
  • vatiquinone
  • vatiquinone

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05515536Phase 3Nov 1, 2022PTC Therapeutics
NCT05485987Phase 2Aug 15, 2022PTC Therapeutics
NCT05218655Phase 3Jun 21, 2022PTC Therapeutics
NCT04577352Phase 2/Phase 3 (Phase 3)Nov 23, 2020PTC Therapeutics
NCT04378075Phase 2/Phase 3 (Phase 3)Sep 1, 2020PTC Therapeutics
NCT02300753N/ANov 21, 2014Bioelectron
NCT02226458Phase 2Oct 1, 2014Bioelectron
NCT02257983Phase 2Oct 1, 2014Bioelectron, University of Florida
NCT02104336Phase 2Aug 1, 2014Bioelectron
NCT02352896Phase 2Jan 1, 2014Bioelectron, Northeast Ohio Medical University
NCT01962363Phase 2Oct 1, 2013Bioelectron, Friedreich's Ataxia Research Alliance (FARA), University of South Florida
NCT01923584Phase 2Sep 1, 2013Bioelectron, University of South Florida
NCT01793090Phase 2Jan 1, 2013Bambino Gesù Hospital and Research Institute, Catholic University of Sacred Heart, Rome
NCT01822249Phase 2Jan 1, 2013Bioelectron
NCT01728064Phase 2Dec 1, 2012Bioelectron
NCT01721733Phase 2Oct 1, 2012Axio Research Corporation, Bioelectron
NCT01719523Phase 1Oct 1, 2012Bioelectron, Rembrandt Foundation, Yale University
NCT01642056Phase 2Jun 22, 2012National Human Genome Research Institute (NHGRI)
NCT01370447Phase 2Feb 1, 2010Bioelectron, Stanford University
NCT07159139N/A—Medical University of South Carolina, PTC Therapeutics
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (14)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BioelectronFor profit12932010
PTC TherapeuticsFor profit6532020
University of South FloridaAcademic/Hospital2212013
Axio Research CorporationFor profit1012012
Bambino Gesù Hospital and Research InstituteAcademic/Hospital1112013
Catholic University of Sacred Heart, RomeAcademic/Hospital1012013
Friedreich's Ataxia Research Alliance (FARA)Academic/Hospital1012013
Medical University of South CarolinaAcademic/Hospital111—
National Human Genome Research Institute (NHGRI)Government1112012
Northeast Ohio Medical UniversityAcademic/Hospital1012014
Rembrandt FoundationAcademic/Hospital1012012
Stanford UniversityAcademic/Hospital1012010
University of FloridaAcademic/Hospital1012014
Yale UniversityAcademic/Hospital1112012
14 organizations
Page 1 / 1